Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome

Inclusion Criteria: * Patients with confirmed Cushing's syndrome \[i.e. ectopic corticotropin syndrome, adrenal adenoma, adrenal carcinoma, ACTH-Independent Macronodular Adrenal Hyperplasia (AIMAH), or Primary Pigmented Nodular Adrenal Dysplasia (PPNAD)\] * For patients on medical treatment for hypercortisolism due to Cushing's syndrome, the washout periods had to be completed prior to baseline efficacy assessments Exclusion Criteria: * Patients with Cushing's disease * History of hypersensitivity to osilodrostat or to drugs of similar chemical classes * History of malignancy of any organ system, treated or untreated, within the past 5 years * Patients receiving treatment for within 4 weeks or ≤5 x half-life of the agent (whichever is longer) before first dose of osilodrostat * Patients with risk factors for QTc prolongation or Torsade de Pointes